Why sglt 2 inhibitors are contraindicated in t1dm
Reading File
Searching the Web
SGLT2 inhibitors type 1 diabetes contraindicated diabetic ketoacidosis FDA safety
Searching PubMed
SGLT2 inhibitors AND type 1 diabetes
Finding Sources
Reading Web Page
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/20…
SGLT2 inhibitors are generally not used in type 1 diabetes because they substantially increase the risk of diabetic ketoacidosis (DKA), often with only mildly elevated or normal glucose, called euglycemic DKA.
Why this happens
- SGLT2 inhibitors cause urinary glucose loss. Blood glucose falls even if insulin is insufficient.
- A person with T1DM may then reduce insulin, or have an unrecognized relative insulin deficiency.
- Low effective insulin plus higher glucagon promotes fat breakdown and hepatic ketone production.
- Glycosuria masks the usual marked hyperglycemia of DKA, so diagnosis can be delayed.
Common triggers include missed/reduced insulin doses, fasting or a low-carbohydrate diet, vomiting/illness, dehydration, surgery, excess alcohol, and insulin-pump failure.
Thus, the glucose-lowering benefit does not outweigh the DKA risk for routine T1DM treatment. FDA labeling notes that, in T1DM trials, ketoacidosis occurred more often with SGLT2 inhibitors than placebo, and can occur with glucose below 250 mg/dL. FDA prescribing information
Strictly speaking, in many product labels this is phrased as “not indicated” or “not recommended” for T1DM rather than an absolute pharmacologic contraindication. The central reason remains the same: increased, potentially life-threatening euglycemic DKA risk. This mechanism is also described in Katzung’s Basic and Clinical Pharmacology, where off-label T1DM use is associated with euglycemic DKA.
This is a shared conversation. Sign in to Orris to start your own chat.